

Tel. : (+302610) 962336 E-mail: epapad@upatras.gr Click here for a [short CV](#)

EDUCATION

University: Department of Pharmacy, School of Health Sciences, University of Patras, Patras, Greece; 1985-1989. Degree: B. Pharm

Graduate: Department of Medicine, School of Health Sciences, University of Patras, Patras, Greece; 1990-1994; Degree: Ph.D. in Pharmacology

Postdoctoral: School of Health Sciences, University of Patras, Patras, Greece; 1994-1995; School of Natural Sciences, University of Patras, Patras, Greece; 1996 School of Health Sciences, University of Patras, Patras, Greece; 1997-1998

ACADEMIC APPOINTMENTS

1991-1994: Research Assistant at the University of Wisconsin Medical School, Milwaukee Clinical Campus, Wisconsin, U.S.A

1995-1997: Assistant Professor of Pharmacology at the Department of Nursing, Faculty of Professions of Health and Providence, Higher technological and Educational Institute of Patras, Greece

1998-2003: Lecturer, 2003-2009: Assistant Professor, 2009-2015: Associate Professor and 2015-present: Professor of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece.

January 2015: Visiting Professor at the Academic Unit of Orthopaedic and Trauma Surgery, University of Leeds, UK.

CURRENT FOCUS OF RESEARCH

- Angiogenesis and tumor growth in vivo and in vitro. Pharmacological studies on the mechanisms involved, and evaluation of new compounds or nanoparticles for their anti-angiogenic and anti-tumor activity.
- The biological actions of the heparin-binding growth factor pleiotrophin. Effects on endothelial cell functions, angiogenesis, tumor growth and metastasis, bone cell biology. Signaling and receptors identification. Structure-function studies and development of therapeutic applications.
- The role of receptor RPTPbeta/zeta in the cardiovascular and the skeletal system. Structure-function studies.

PUBLICATIONS

International Journals with referees : 86

Greek Journals: 5 Books: 17

Conference proceedings with referees: 97

Conference proceedings without referees: 169

TEACHING ACTIVITIES

Undergraduate:

- Pharmacology I and II
- Molecular Pharmacology

- Introduction to Pharmaceutical Sciences

Postgraduate:

- Preclinical and Clinical Drug Evaluation
- Molecular Targets of Drug Action
- Precision Therapeutics

SELECTED PUBLICATIONS

1. Mikelis C, Sfaelou E, Koutsioumpa M, Kieffer N, **Papadimitriou E**. Integrin $\alpha v\beta 3$ is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase β/ζ . *FASEB J* 23:1459-1469, 2009.

2. Koutsioumpa M, Polytaichou C, Courty J, Zhang Y, Kieffer N, Mikelis C, Skandalis S, Hellman U, Iliopoulos D, **Papadimitriou E**. Interplay between alpha v beta 3 integrin and nucleolin regulates human endothelial and glioma cell migration. *J Biol Chem* 288:343-354, 2013.

3. Koutsioumpa M, Poimenidi E, Pantazaka E, Theodoropoulou C, Skoura A, Megalioikonomou V, Kieffer N, Courty J, Mizumoto S, Sugahara K, **Papadimitriou E**. Receptor protein tyrosine phosphatase beta/zeta is a functional binding partner for vascular endothelial growth factor. *Mol Cancer*, 14:19, 2015.

4. **Papadimitriou E**, Pantazaka E, Castana P, Tsalios T, Polyzos A, Beis D. Pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta as regulators of angiogenesis and cancer. *BBA Reviews on Cancer* 1866:252-265, 2016.

5. Lampropoulou E, Logoviti I, Koutsioumpa M, Hatziapostolou M, Polytaichou C, Skandalis SS, Hellman U, Fousteris M, Nikolaropoulos S, Choleva E, Skoura A, Megalioikonomou V, **Papadimitriou E**. Cyclin-dependent kinase 5 mediates pleiotrophin-induced endothelial cell migration. *Sci Rep* 8:5893, 2018.

6. Kastana P, Choleva E, Poimenidi E, Karamanos N, Sugahara K, **Papadimitriou E**. Insight into the role of chondroitin sulfate E in angiogenesis. *FEBS J* 2019; doi: 10.1111/febs.14830.